Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) from a strong sell rating to a hold rating in a research note issued to investors on Tuesday morning.
According to Zacks, “Sucampo is focused on expanding its sole marketed product, Amitiza’s label and penetrating into new markets. Moreover, the company’s collaborations with firms like Takeda and Mylan for the commercialization of Amitiza is a big positive. In addition, through the agreement with Cancer Prevention Pharmaceuticals, the company acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America. Moreover, with acquisition of Vtesse, Sucampo added a late stage program in Niemann-Pick Disease type C1 to its pipeline. However, Sucampo’s dependence on Amitiza for growth is concerning. Also, some companies are trying to market and sell generic version of Amitiza. Any decline in Amitiza's sales will adversely impact the top-line. Moreover, it is no stranger to pipeline setbacks. The company has lowered its earnings guidance to incorporate the Vtesee acquisition.”
Other research analysts have also recently issued reports about the stock. Maxim Group set a $19.00 price objective on shares of Sucampo Pharmaceuticals and gave the stock a buy rating in a research report on Saturday, March 11th. Roth Capital set a $27.00 price objective on shares of Sucampo Pharmaceuticals and gave the stock a buy rating in a research report on Saturday, March 11th. WallachBeth Capital decreased their price objective on shares of Sucampo Pharmaceuticals from $20.00 to $15.00 and set a buy rating on the stock in a research report on Friday, March 10th. Jefferies Group LLC decreased their price objective on shares of Sucampo Pharmaceuticals from $13.00 to $11.00 and set a hold rating on the stock in a research report on Thursday, May 4th. Finally, Mizuho restated a buy rating and issued a $14.00 price objective on shares of Sucampo Pharmaceuticals in a research report on Tuesday, April 4th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Sucampo Pharmaceuticals presently has an average rating of Buy and an average price target of $16.71.
Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at 10.625 on Tuesday. Sucampo Pharmaceuticals has a 12-month low of $9.30 and a 12-month high of $17.55. The company has a market capitalization of $493.68 million, a price-to-earnings ratio of 17.708 and a beta of 1.46. The firm has a 50-day moving average of $10.28 and a 200 day moving average of $11.25.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings data on Wednesday, May 3rd. The biopharmaceutical company reported $0.23 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.28 by $0.05. The company had revenue of $56.30 million during the quarter, compared to the consensus estimate of $54.15 million. Sucampo Pharmaceuticals had a return on equity of 43.27% and a net margin of 11.36%. The firm’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same quarter last year, the company posted $0.21 earnings per share. Analysts expect that Sucampo Pharmaceuticals will post $1.04 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Louisiana State Employees Retirement System acquired a new position in shares of Sucampo Pharmaceuticals during the first quarter worth approximately $111,000. Envestnet Asset Management Inc. acquired a new position in shares of Sucampo Pharmaceuticals during the fourth quarter worth approximately $115,000. Karp Capital Management Corp acquired a new position in shares of Sucampo Pharmaceuticals during the first quarter worth approximately $119,000. Capstone Asset Management Co. acquired a new position in shares of Sucampo Pharmaceuticals during the first quarter worth approximately $133,000. Finally, New York State Teachers Retirement System acquired a new position in shares of Sucampo Pharmaceuticals during the first quarter worth approximately $137,000. Institutional investors and hedge funds own 57.00% of the company’s stock.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285157/sucampo-pharmaceuticals-inc-nasdaqscmp-upgraded-to-hold-by-zacks-investment-research.html
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.